Fragile X-associated tremor/ataxia syndrome presenting in a woman after chemotherapy.
O'Dwyer
J P
JP
Department of Neurology, St. Vincent's University Hospital, Dublin 4, Ireland. drjpodwyer@eircom.net
Clabby
C
C
Crown
J
J
Barton
D E
DE
Hutchinson
M
M
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001284:Atrophy / Q000139:chemically induced / Q000235:genetics / Q000503:physiopathology; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016190:Carboplatin / Q000009:adverse effects; D002277:Carcinoma / Q000188:drug therapy* / Q000556:secondary; D002524:Cerebellar Ataxia / Q000139:chemically induced* / Q000235:genetics* / Q000503:physiopathology; D002531:Cerebellum / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D004351:Drug Resistance / Q000235:genetics; D005260:Female; D051860:Fragile X Messenger Ribonucleoprotein 1 / Q000235:genetics; D005600:Fragile X Syndrome / Q000235:genetics*; D020022:Genetic Predisposition to Disease / Q000235:genetics; D006579:Heterozygote; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008279:Magnetic Resonance Imaging
D016190:Carboplatin; D051860:Fragile X Messenger Ribonucleoprotein 1; C497683:FMR1 protein, human